Hedera Dx, a Swiss techbio company advancing precision cancer care, announced the successful close of a €15 million Series A financing round led by Vsquared Ventures. The round included new investor Tesi and strong support from existing backers including Helsana HealthInvest, Eyrir Venture Management, Inventure, and Top Harvest.
The funding will accelerate Hedera Dx's mission to eliminate systemic barriers preventing cancer patients from accessing targeted therapies through its innovative decentralized liquid biopsy platform.
Transforming Cancer Diagnostics Through Decentralization
Rather than operating its own commercial laboratory, Hedera Dx enables hospitals to perform advanced blood-based cancer diagnostics in-house. The company provides a comprehensive 32-gene circulating tumor DNA (ctDNA) panel, standardized lab protocols compatible with existing next-generation sequencing (NGS) instruments, and a cloud-based software layer for variant calling and clinical interpretation.
This approach addresses a critical challenge in European healthcare systems, where cancer diagnostics must often be performed within hospital laboratories rather than centralized labs. By equipping hospital labs to run liquid biopsies themselves, the company cuts turnaround time from 10-14 days down to under 48 hours.
"At Hedera, we are building the infrastructure to make precision cancer care accessible to every patient and clinician — globally," said Tommi Lehtonen, CEO and co-founder. "There are many personalized cancer treatments available, but far too many patients can't access them. Our technology empowers hospital labs to change that."
Rapid European Expansion
The platform is already deployed in hospital labs across 11 European countries, including Switzerland, Germany, France, Italy, Spain, and the Netherlands. These deployments span public hospitals and regional cancer centers, demonstrating the practicality of Hedera's model for institutions without extensive genomics research capabilities.
The company's AI-native solution not only delivers advanced molecular profiling to guide physicians' treatment decisions but also generates real-world, patient-centric insights to support the development of future oncology therapies.
Real-World Evidence Generation
Hedera Dx is actively collaborating with leading cancer centers and patient organizations to generate clinicogenomic evidence through its Hedera Frame platform. This global, prospective, patient-centric data hub gathers clinical information, tumor genomics data, and resulting outcomes from patients with solid tumors who have undergone NGS-based molecular testing.
One notable initiative is the EMPATHY NSCLC study, the first prospective clinical validation and real-world utility study for the European, NGS-based decentralized liquid biopsy approach. This multicenter study enables real-world assessment of current ctDNA-based liquid biopsy practices in hospital laboratories across a dozen leading European cancer centers.
To enhance patient engagement, Hedera Dx has developed the myHedera app, which enables patients to actively participate in their care by providing Patient-Reported Outcomes and Patient-Reported Experience Measures.
Strategic Investment and Market Position
"Hedera Dx is addressing a critical gap in oncology care," said Dr. Lise Rechsteiner, General Partner at Vsquared Ventures. "Their in-house diagnostics model increases patient access to testing and enables more effective treatment. Combined with their real-world data capabilities, Hedera is poised to lead precision oncology in healthcare systems beyond the U.S."
The decentralized model offers several advantages for European healthcare systems, including keeping data local, respecting institutional autonomy, and integrating with standard lab equipment already in use. This approach also allows hospitals to maintain ownership of their clinical data while participating in shared real-world evidence networks.
Future Development Plans
With the new funding, Hedera Dx will continue expanding its commercial footprint and enhance its real-world data infrastructure. The company plans to accelerate development of new assays for minimal residual disease and early detection while expanding its analytics capabilities.
"We're not just improving access," added Dr. Christian Meisel, CMO and co-founder. "We're building a platform that delivers actionable real-world insights and accelerates the development of life-saving therapies."
The investment will support deeper integration into hospital informatics, more robust compliance infrastructure, and tighter feedback between lab users and the central team to fine-tune protocols and analytics. The company aims to strengthen its position in the global oncology market and bring precision medicine to more patients across Europe and beyond.
